Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients

Elios Therapeutics presented a subgroup analysis of the prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine, in patients with Stage III and IV resected melanoma.